NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,886,004 | -58.7% | 6,435,518 | 0.0% | 0.23% | -43.1% |
| Q2 2023 | $16,667,992 | -36.5% | 6,435,518 | 0.0% | 0.41% | -51.8% |
| Q1 2023 | $26,256,913 | -18.7% | 6,435,518 | 0.0% | 0.85% | -13.9% |
| Q4 2022 | $32,306,300 | +356.4% | 6,435,518 | +1089.3% | 0.98% | +370.3% |
| Q3 2022 | $7,078,000 | +2.0% | 541,108 | 0.0% | 0.21% | -12.6% |
| Q2 2022 | $6,937,000 | -15.9% | 541,108 | 0.0% | 0.24% | -7.4% |
| Q1 2022 | $8,252,000 | +65.0% | 541,108 | +120.9% | 0.26% | +48.3% |
| Q3 2021 | $5,000,000 | +76.6% | 245,000 | +70.7% | 0.17% | +64.2% |
| Q2 2021 | $2,831,000 | -32.2% | 143,567 | 0.0% | 0.11% | -42.7% |
| Q1 2021 | $4,173,000 | -4.0% | 143,567 | 0.0% | 0.18% | -20.9% |
| Q4 2020 | $4,349,000 | -6.3% | 143,567 | -54.7% | 0.23% | -50.1% |
| Q2 2019 | $4,639,000 | – | 316,900 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |